{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:04:41Z","timestamp":1775239481695,"version":"3.50.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Joint Construction Project of Henan Provincial Medical Science and Technology Research Program","award":["LHGJ20210343"],"award-info":[{"award-number":["LHGJ20210343"]}]},{"name":"Open Research Project of Sichuan Provincial Key Laboratory of Ultrasound Cardiac Electrophysiology and Biomechanics","award":["2021KFKT01"],"award-info":[{"award-number":["2021KFKT01"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Hypertension is one of the main causes of cardiovascular diseases worldwide, affecting over one billion people. Although aliskiren offers a valuable option for inhibiting the renin-angiotensin system, its safety profile in the real world remains insufficiently explored, especially for rare or under-recognized adverse events (AEs), which have not been fully clarified. Therefore, leveraging large-scale post-marketing surveillance data is crucial for identifying rare AEs and guiding safer clinical practice. This study aims to elucidate pharmacovigilance signals associated with aliskiren (an antihypertensive drug) by systematically analyzing the characteristics of adverse events (AEs) from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database and WHO-VigiAccess database, which provides a reliable scientific basis for clinical practice and regulatory decision-making. We conducted a retrospective quantitative analysis of aliskiren-related AE reports from the aforementioned two databases, employing the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS) algorithms for signal detection. The results indicate that there were 5,596 and 5,549 aliskiren-related reports in the FAERS and WHO-VigiAccess databases, respectively. The median duration of these AEs during the observation period was 62 days, with an interquartile range (IQR) of 7\u2013282 days. In both databases, signals for aliskiren were distributed across 28 System Organ Classes (SOCs), among which investigations, cardiac disorders, renal and urinary disorders, vascular disorders, and metabolism and nutrition disorders exhibited significant signals based on specific criteria applied across the four algorithms. A total of 607 preferred terms (PTs) with significant disproportionality signals were detected using the four algorithms, including potential AEs not previously well-documented, such as palpitations, myalgia, proteinuria, muscular weakness, pulmonary edema, and pollakiuria. This study not only confirms the known adverse reactions of aliskiren but also uncovers new potential risks, highlighting the importance of strengthening drug safety monitoring to enhance therapeutic efficacy and reduce the risk of adverse reactions. It provides valuable safety insights for physicians considering the use of aliskiren in the management of primary hypertension.<\/jats:p>","DOI":"10.1371\/journal.pone.0346326","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:29:36Z","timestamp":1775237376000},"page":"e0346326","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety of aliskiren in primary hypertension: A cross-database study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8213-1236","authenticated-orcid":true,"given":"Meirong","family":"Shan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruofei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanyu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinchuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"33","key":"pone.0346326.ref001","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"B Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"pone.0346326.ref002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1524-6175.2007.08134.x","article-title":"Risk-based classification of hypertension and the role of combination therapy","volume":"10","author":"MR Weir","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"7","key":"pone.0346326.ref003","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cpcardiol.2017.03.001","article-title":"Clinical perspective on antihypertensive drug treatment in adults with grade 1 hypertension and low-to-moderate cardiovascular risk: An international expert consultation","volume":"42","author":"A Morales Salinas","year":"2017","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"pone.0346326.ref004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"KT Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"pone.0346326.ref005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/ijms19020455","article-title":"The Impact of Vitamin D in the treatment of essential hypertension","volume":"19","author":"C Legarth","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"10304","key":"pone.0346326.ref006","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"(NCD-RisC) NCD Risk Factor Collaboration","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"pone.0346326.ref007","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2025.4390","article-title":"Antihypertensive medication timing and cardiovascular events and death: The bedmed randomized clinical trial","volume":"333","author":"SR Garrison","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"pone.0346326.ref008","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1592\/phco.29.2.193","article-title":"Aliskiren: An oral direct renin inhibitor for the treatment of hypertension","volume":"29","author":"CA Sanoski","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"5","key":"pone.0346326.ref009","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2125.2009.03504.x","article-title":"Aliskiren","volume":"68","author":"EA Dubois","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"pone.0346326.ref010","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.108.787630","article-title":"Aliskiren","volume":"118","author":"MJ Brown","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"pone.0346326.ref011","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/eurjhf\/hfr034","article-title":"Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: The Aliskiren Observation of Heart Failure Treatment study","volume":"13","author":"B Pitt","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"pone.0346326.ref012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10557-011-6319-3","article-title":"Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: A retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial","volume":"25","author":"NP Sidik","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"pone.0346326.ref013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1470320311417272","article-title":"Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: An AVOID substudy","volume":"13","author":"F Persson","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"1","key":"pone.0346326.ref014","doi-asserted-by":"crossref","first-page":"36558","DOI":"10.1038\/s41598-025-19679-z","article-title":"Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database","volume":"15","author":"Q Guo","year":"2025","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0346326.ref015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"KJ Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0346326.ref016","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"pone.0346326.ref017","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"SA Rivkees","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"pone.0346326.ref018","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - A comparison of three different disproportionality measures","volume":"15","author":"PS Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0346326.ref019","doi-asserted-by":"crossref","first-page":"1561020","DOI":"10.3389\/fphar.2025.1561020","article-title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","volume":"16","author":"H Hu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"8","key":"pone.0346326.ref020","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"AH Gradman","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"pone.0346326.ref021","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1751-7176.2011.00483.x","article-title":"Comparative efficacy and safety of combination aliskiren\/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension","volume":"13","author":"HR Black","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"pone.0346326.ref022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/VHRM.S63725","article-title":"Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: A substudy of AGELESS","volume":"10","author":"F Baschiera","year":"2014","journal-title":"Vasc Health Risk Manag"},{"issue":"9","key":"pone.0346326.ref023","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/jhh.2009.107","article-title":"Aliskiren for geriatric lowering of systolic hypertension: A randomized controlled trial","volume":"24","author":"DA Duprez","year":"2010","journal-title":"J Hum Hypertens"},{"issue":"1","key":"pone.0346326.ref024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.17996\/anc.21-00139","article-title":"Efficacy of add-on therapy with carvedilol and the direct renin inhibitor aliskiren for improving cardiac sympathetic nerve activity, cardiac function, symptoms, exercise capacity and brain natriuretic peptide in patients with dilated cardiomyopathy","volume":"7","author":"T Toyama","year":"2021","journal-title":"Ann Nucl Cardiol"},{"issue":"4","key":"pone.0346326.ref025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1470320313510584","article-title":"Aliskiren and losartan trial in non-diabetic chronic kidney disease","volume":"15","author":"K-T Woo","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"4","key":"pone.0346326.ref026","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Y Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"5","key":"pone.0346326.ref027","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/2040622313495288","article-title":"Aliskiren: Review of efficacy and safety data with focus on past and recent clinical trials","volume":"4","author":"S Sen","year":"2013","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"pone.0346326.ref028","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/eurjhf\/hfs033","article-title":"Aliskiren, ALTITUDE, and the implications for ATMOSPHERE","volume":"14","author":"JJ McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"26","key":"pone.0346326.ref029","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/eurheartj\/ehu079","article-title":"Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: The APOLLO trial","volume":"35","author":"KK Teo","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0346326.ref030","doi-asserted-by":"crossref","first-page":"22623","DOI":"10.1038\/s41598-023-49649-2","article-title":"Role of the autonomic nervous system in young, middle-aged, and older individuals with essential hypertension and sleep-related changes in neurocardiac regulation","volume":"13","author":"C-H Yeh","year":"2023","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:29:41Z","timestamp":1775237381000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346326"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346326","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}